In the present study, three EGFR inhibitors (erlotinib, apatinib and icotinib) were evaluated to determine the optimal combination with DOX for the treatment of NSCLC cell lines (A549, NCI-H1975 and PC9). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.